Published in Gene Therapy Weekly, March 14th, 2002
In September 2001 Introgen changed its fiscal year end from June 30 to December 31. Introgen reported a net loss of $6.2 million, or $0.29 per share, for the quarter ended December 31, 2001, and a net loss of $12.3 million or $0.58 per share, for the 6 months ended December 31, 2001. These results compare to a net loss of $2.4 million, or $0.13 per share, for the quarter December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.